Print

immatics biotechnologies GmbH Appoints Peter Chambre as Chairman  
11/12/2012 1:10:08 PM

Tuebingen, 12. November 2012 – immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.

Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.

Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.

Paul Higham, CEO of immatics, said: “I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter’s experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors.”

Peter Chambré said: “immatics’ vaccines, based on the Company’s highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics’ lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders.”

For additional information on immatics please visit www.immatics.com or contact:

Paul Higham, CEO

Dr. Nikola Wiegeler, Assistant to the Management

immatics biotechnologies GmbH

Phone: +49 7071 5397 110

E-mail: media@immatics.com

Citigate Dewe Rogerson

David Dible / Chris Gardner / Sita Shah

Phone: +44 207 638 9571

E-mail: david.dible@citigatedr.co.uk

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.

immatics’ unique technology platform XPRESIDENTTM discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics’ TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells.

immatics’ vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.

immatics’ multi-peptide vaccines are ‘drug like’, i.e. fully synthetic, off-the-shelf, easily scalable and stable.

immatics is based in Tuebingen and Martinsried (Munich), Germany.


//-->